Nitisinone 10 mg tablet high compritol    (DrugBank: Nitisinone)

2 diseases
IDDisease name (Link within this page)Number of trials
164Oculocutaneous albinism0
241Hypertyrosinemia type I1

164. Oculocutaneous albinism    [ 15 clinical trials,   57 drugs,   (DrugBank: 34 drugs),   34 drug target genes,   136 drug target pathways]
Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 15 trial found

241. Hypertyrosinemia type I    [ 14 clinical trials,   7 drugs,   (DrugBank: 1 drug),   1 drug target gene,   5 drug target pathways]
Searched query = "Hypertyrosinemia type I", "Tyrosinemia type I", "Tyrosinemia I", "Hereditary tyrosinemia, Type I", "Fumarylacetoacetate hydrolase deficiency", "FAH deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 14 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02750709
(ClinicalTrials.gov)
October 201520/4/2016Bioequivalence Study of Two Nitisinone Formulations Compared to OrfadinA Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 Healthy Male and Female Subjects Under Fasting ConditionsHereditary Tyrosinemia, Type IDrug: Nitisinone;Drug: Nitisinone 10 mg Tablet High Compritol;Drug: OrfadinCycle Pharmaceuticals Ltd.ParexelCompleted18 Years55 YearsAll24Phase 1South Africa